Search Results for "Psychiatry"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Psychiatry. Results 151 to 159 of 159 total matches.

Ropinirole for Restless Legs Syndrome

   
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005  (Issue 1214)
Neurosurg Psychiatry 2004; 75:92. 10. AS Walters et al. Ropinirole is effective in the treatment ...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Med Lett Drugs Ther. 2005 Aug 1;47(1214):62-4 |  Show IntroductionHide Introduction

Focalin XR for ADHD

   
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009  (Issue 1308)
-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008; 47:199. 5. R Silva et al ...
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing.
Med Lett Drugs Ther. 2009 Mar 23;51(1308):22-4 |  Show IntroductionHide Introduction

Deep Brain Stimulation for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009  (Issue 1309)
in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76:1640. 7. P Krack et al. Five ...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Med Lett Drugs Ther. 2009 Apr 6;51(1309):26-7 |  Show IntroductionHide Introduction

Drugs for Female Sexual Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010  (Issue 1353)
bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005 ...
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Med Lett Drugs Ther. 2010 Dec 13;52(1353):100-2 |  Show IntroductionHide Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019 October 28 (epub). 23 ...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 |  Show IntroductionHide Introduction

Drugs for Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020  (Issue 1596)
disorder and autism spectrum disorder in childhood. JAMA Psychiatry 2020; 77:180. 17. Duloxetine ...
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Med Lett Drugs Ther. 2020 Apr 20;62(1596):57-62 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
Neurosurg Psychiatry 2020; 91:795. 2. MJ Armstrong and MS Okun. Diagnosis and treatment of Parkinson ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
with depression. JAMA Psychiatry 2016; 73:1154. 17. FDA Guidance Document. Labeling for combined hormonal ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
facts and common misconceptions. 
Ann Gen Psychiatry 2024; 23:11. 34. M Mula et al. Antiepileptic ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction